Filing Flows › Pacira BioSciences (PCRX) › Q2 2026 › vs Q1 2026
Pacira BioSciences (PCRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Pacira BioSciences's revenue rose $15.0M (+8%) from $177M in Q1 2026 to $192M in Q2 2026. Operating margin 2.2% against 3.9% (-1.7 pts).
Pacira BioSciences, Q2 2026: revenue $192M (+6% year over year), operating margin 2.2%, net earnings $4.7M, operating cash flow $57.5M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 2.2% | 3.9% | -1.7 pts |
| Net margin | 2.4% | 1.6% | +0.8 pts |
| Free cash flow margin | 29.2% | 12.9% | +16.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $192M | $177M | $15.0M | +8% |
| Operating profit | $4.3M | $6.9M | −$2.6M | -38% |
| Costs & expenses | $188M | $170M | $17.7M | +10% |
| Pre-tax earnings | $2.6M | $5.0M | −$2.4M | -49% |
| Other expense, net | $1.7M | $1.9M | −$192K | -10% |
| Cost of revenue | $44.2M | $36.4M | $7.8M | +21% |
| Research & development | $30.2M | $28.1M | $2.2M | +8% |
| SG&A | $91.8M | $93.9M | −$2.1M | -2% |
| Other operating costs | $21.9M | $12.0M | $9.9M | +82% |
| Income tax benefit | $2.1M | −$2.1M | $4.2M | — |
| Net earnings | $4.7M | $2.9M | $1.7M | +60% |
| Depreciation & amortization | $21.3M | $21.3M | −$36K | -0.2% |
| Share-based compensation | $15.0M | $13.5M | $1.4M | +10% |
| Working capital & other | $16.6M | −$12.1M | $28.7M | — |
| Operating cash flow | $57.5M | $25.7M | $31.8M | +124% |
| Free cash flow (OCF − capex) | $56.1M | $23.0M | $33.2M | +144% |
| Capital expenditures | $1.3M | $2.7M | −$1.4M | -51% |
Questions
How much did Pacira BioSciences's revenue grow quarter over quarter in Q2 2026?
Pacira BioSciences's revenue rose $15.0M (+8%) from $177M in Q1 2026 to $192M in Q2 2026. Operating margin 2.2% against 3.9% (-1.7 pts).